Systemic lupus erythematosus (SLE) is an autoimmune disease, which results in various organ pathologies. However, current treatment towards SLE is suboptimal.
play a key role in immune dysfunction, mediating tissue inflammation and organ damage in SLE. 7 TNF-a levels were found to increase in patients with SLE and were associated with the disease activity of SLE. The blocking of TNF-a function in patients with SLE decreased the disease severity. 8, 9 In addition, in humans and mice with lupus nephritis, IL-6 promoted autoantibody production and was correlated with the SLE activity. 10, 11 Therefore, the restrain of the inflammatory response could facilitate the improvement of SLE.
While and the leakage of cell contents, to avoid the so-called secondary necrosis of apoptotic cells. 12, 13 Following the phagocytosis of apoptotic cells, macrophages can produce and release anti-inflammatory cytokines, such as TGF-b, 14 which play an immune regulatory role, and avoid the activation of the immune response to autoantigens and autoimmunity. However, in SLE, the ability of apoptotic cell clearance is deficient, leading to the accumulation of the apoptotic cells, resulting to the secondary necrosis of apoptotic cells and the subsequent activation of self-immune response. 15 Therefore, the regulation of macrophage function plays an important role in maintaining homeostasis and inhibiting the occurrence of autoimmune diseases.
Erythropoietin (EPO) is a larvaceous cytoprotective glycoprotein that was initially identified as an essential growth factor of haemopoiesis through the homodimer EPO receptor (EPOR 2 ) and widely applied to treat the anaemia. 16 However, EPORs were found to be expressed in macrophages, [17] [18] [19] and EPO signalling inhibited inflammatory gene expression in macrophages. 20, 21 Moreover, recently, we found that EPO promoted macrophage phagocytosis of dying cells and the progression of SLE was ameliorated by exogenous EPO treatment. 22 In addition, accumulated studies had also shown that EPO can be cytoprotective following tissue injury, indicating that EPO treatment has pronounced anti-inflammatory and antiapoptotic capacities. 23, 24 Therefore, EPO might be a candidate drug for SLE therapy, but the long-term use of EPO has been shown to raise the risk of adverse side effects, such as thromboembolism and hypertension. 25 Fortunately, recent studies have shown that EPO exerted its anti-inflammatory and cytoprotective functions via the EPOR-CD131
complex. In contrast, the haematopoietic function of EPO is considered to act through the high-affinity homodimer of EPOR For pristane-induced SLE model, female C57BL/6 mice, at 10-12 weeks of age, were given a single intraperitoneal injection of 0.5 mL of pristane (Sigma-Aldrich) to induce SLE-like autoimmunity.
At the end of the indicated experimental period, animals were killed and specimens including blood, spleen, thymus and kidney were collected.
| ARA290 intervention
For therapy, MRL/lpr mice and C57BL/6 mice received intraperitoneal injection of ARA290 (peptide biochemical GmbH, Hangzhou, China; endotoxin-free with N90% purity; 500 lg/kg/d) once daily for 3 months (6 mice/group). And the same volume of PBS was given to the control group (6 mice/group). The dosage of ARA290
was chosen according to our previous study. Kit and Urea Assay Kit (Jiancheng, Nanjing) according to the manufacturer's instructions. (Gibco, Grand Island, NY) containing penicillin (100 U/mL), streptomycin (100 U/mL) and 10% foetal calf serum at 37°C and 5% CO 2 .
| Flow cytometry
To confirm effects of ARA290 on inflammatory response, 
| Statistical analysis
Data were calculated with a statistical software package (GraphPad Prism 5.0 for Windows). Data were presented as the means AE SEM, and the group mean values were analysed by the two-tailed unpaired Student's t test. For all statistical analyses, statistical significance is indicated by a single asterisk (P < .05), 2 asterisks (P < .01) or 3 asterisks (P < .001).
3 | RESULTS
| ARA290 treatment Ameliorates Lupuslike symptoms in pristane-induced SLE mice
We first investigated whether ARA290 altered the development of lupuslike autoimmune disease with the pristane-induced murine lupus model, which is characterized by the production of autoantibodies and development of glomerulonephritis, resembling the key features of human SLE. Moreover, pristane also leads to persistent apoptosis of immature monocytes in ectopic lymphoid tissue that forms in response to the hydrocarbon. Eight weeks following pristane injection, ARA290 was given to this SLE mice once daily for 12 weeks ( Figure 1A) .
One of the most reliable criteria for SLE is an increase in antinuclear antigen autoantibodies in the serum. 38 A significant decrease in the serum concentrations of anti-dsDNA antibodies (ADA) and antinuclear antibodies (ANA) was observed in ARA290-treated SLE mice compared to the control mice ( Figure 1B ). Another hallmark of SLE is the deposition of autoantibodies as immune complexes in the kidney, leading to inflammation and destruction of the glomeruli. Following ARA290 treatment, the deposition of IgG and complement C3 in glomerulus was significantly reduced than in control mice (Figure 1C, D) . Furthermore, reduced glomerular size and cellularity were observed in kidney sections from ARA290-treated mice than from their vehicle counterparts ( Figure 1E ). In line with the pathological changes in the kidney, the levels of creatinine and blood urea nitrogen in serum were greatly decreased following ARA290 treatment compared to the control ( Figure 1F) . Accordingly, reduced levels of diuresis and urine albumin and increased levels of urine creatinine were found in the ARA290-treated mice compared to that of the vehicle control group ( Figure 1G ). In addition, the bodyweight of the ARA290-treated SLE mice was greatly higher than that of the control SLE mice, indicating a better outcome. Collectively, these data show that ARA290 treatment produces improvements in lupuslike symptoms in pristane-induced SLE mice.
| ARA290 treatment suppressed inflammatory response in pristane-induced SLE mice
Inflammation plays a vital role in SLE development. In SLE, IL-6, MCP-1, IFN-c and TNF-a promotes the progression of this disease. [39] [40] [41] [42] On the contrary, IL-10 and TGF-b are anti-inflammatory cytokines, which are related to SLE recovery. 14, 43 As shown in Fig In addition, the enlargement of spleen and lymph nodes is related with active inflammatory response and regarded as clinical markers in lupus patients. In current investigation, we found the weight of the spleen and lymph nodes of SLE mice was significant reduced following ARA290 treatment compared to that of the control mice ( Figure 2C ).
Together, these data demonstrate that ARA290 treatment reduced the inflammatory response in pristane-induced SLE mice.
| ARA290 Inhibited Inflammatory Macrophage Activation but Promoted its Phagocytic Activity
Accumulated evidences suggested a more active role of macrophages in mediating tissue inflammation and injury in SLE, including high inflammatory cytokine production and defective phagocytic capacity. 44, 45 Then, we next investigated ARA290 effects on macrophage.
We first studied the ARA290 effects on inflammatory macrophage activation, and LPS was applied to stimulate macrophages. As shown in Figure 3A , B, increased expression of TNF-a and iNOS was detected following LPS stimulation, indicating an inflammatory macrophage activation. And ARA290 dose-dependently suppressed LPS-induced expression of TNF-a and iNOS ( Figure 3A, B) .
The defective apoptotic cell clearance has been linked to autoimmune disease, such as SLE, and the accumulation of apoptotic cells and decreased phagocytotic ability of macrophages in SLE have been
reported. [46] [47] [48] Therefore, we further detected the impact of ARA290 on apoptotic cell clearance by macrophages in vitro by flow cytometry. As shown in Figure 3C , ARA290 dose-dependently promoted macrophage phagocytosis of apoptotic cells. In line with this in vitro observation, we also found that the accumulation of apoptotic cells in kidney of pristane-induced SLE mice was greatly decreased by ARA290 ( Figure 3D ).
Collectively, these data show that ARA290 suppressed macrophage inflammatory activation and promoted macrophage phagocytosis of apoptotic cells.
F I G U R E 1 ARA290 treatment Ameliorates Lupuslike symptoms in pristane-induced SLE mice (A) Eight-week-old female SLE mice were orally administered PBS (n = 6) or ARA290 (n = 6) 3 times a week until the end of study period, and the mice were killed, and kidney was taken for HE and immunohistochemical staining. Collectively, these data show that ARA290 treatment produces improvements in lupuslike symptoms and suppressed inflammation in the MRL/lpr SLE mice. These data demonstrate that ARA290 ameliorated SLE, which at least could be partly due to its anti-inflammatory and apoptotic cell clearance promoting effects, without stimulating haematopoiesis, suggesting that ARA290 could be a hopeful candidate for SLE treatment.
The increased evidence suggested a close link between pro-inflammatory cytokines and SLE. Specifically, up-regulated pro-inflammatory cytokines caused an immune dysregulation and tissue damage. 50, 51 Fox example, studies have revealed that elevated serum levels of TNF-a are positively associated with disease activity as well as renal involvement in patients with SLE. 10, 52 Moreover, IL-6 can be hoisted in the urine of lupus nephritis patients, with higher levels correlating with active renal inflammation and pathology. 53, 54 In addition, monocyte chemoattractant protein (MCP-1) is implicated in the activation of inflammatory cells and has been suggested to affect the progression of lupus nephritis (LN). 55, 56 Macrophages are the main origin of these inflammatory cytokines in SLE. In the current study, our in vivo and in vitro studies
showed that ARA290 ameliorated inflammatory response in SLE mice and, notably, suppressed the expression of TNF-a, IL-6, iNOS and MCP-1 in macrophages, which suggested that ARA290 might alleviated the symptoms of SLE via regulating macrophage inflammatory response; however, the definite mechanism between ARA290 and macrophage inflammatory response needs further investigation.
Our study also provides forceful evidence that ARA290 significantly promote the phagocytic ability of macrophages in vitro and in vivo. SLE is associated with the deposition of apoptotic cells in vivo. 45 Defects in apoptotic cell clearance may result in secondary necrosis and lead to autoimmunity. 45, 57 Research had reported that macrophages are the main phagocytic cells. In 1980s, studies had
shown that the defect phagocytic function of macrophages would lead to abnormal accumulation of apoptotic debris, considered to be SLE macrophages in vivo abnormalities. 58 Our previous study has shown that EPO promotes macrophage phagocytosis of apoptotic cells. 22 In line with this, here we found that the EPO-derived ARA290 peptide also elevated the phagocytotic activity of macrophage to apoptotic cells in vitro. Furthermore, the apoptotic cell accumulation in vivo was also reduced following ARA290 treatment in SLE. Therefore, the therapeutic effects of ARA290 on SLE could be partly due to its activity to promote apoptotic cell clearance.
In conclusion, our investigation here demonstrates that ARA290 ameliorated SLE, which at least could be partly due to its anti-inflammatory and apoptotic cell clearance promoting effects, without stimulating haematopoiesis, suggesting that ARA290 could be a hopeful candidate for SLE treatment.
